Gregory Alan Korbel - Jul 28, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Operating Officer
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Jul 28, 2022
Transactions value $
$0
Form type
4
Date filed
8/1/2022, 05:04 PM
Previous filing
Jun 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +24.3K +113.22% $0.00 45.8K Jul 28, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Option (right to Buy) Award $0 +35.7K $0.00 35.7K Jul 28, 2022 Common Stock 35.7K $1.09 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 8,100 shares on July 28, 2023, (ii) 8,100 shares on July 28, 2024 and (iii) 8,100 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.